Get the Stockscreener App
0.1884
1.10%
-0.0021
Senti Biosciences Holdings Inc stock is traded at $0.1884, with a volume of 366.34K.
It is down -1.10% in the last 24 hours and down -44.26% over the past month.
Senti Biosciences Holdings Inc, formerly known as Senti Biosciences Inc, is a clinical-stage biotechnology company developing cell and gene therapies using its gene circuit platform for patients with incurable diseases. Its gene circuits, created from proprietary DNA sequences, are designed to reprogram cells to sense, compute, and respond to cellular environments. Its product candidates are to kill cancer cells, spare healthy cells, increase specificity, and control drug expression. Its candidate, SENTI-202, is a logic-gated off-the-shelf CAR-NK cell therapy for blood cancers, currently in a Phase 1 clinical trial in the United States and Australia for relapsed or refractory hematological malignancies, including Acute Myeloid Leukemia (AML).
See More
Previous Close:
$0.1905
Open:
$0.185
24h Volume:
366.34K
Relative Volume:
0.15
Market Cap:
$5.87M
Revenue:
$38,000
Net Income/Loss:
$-51.55M
P/E Ratio:
-0.0981
EPS:
-1.9207
Net Cash Flow:
$-37.07M
1W Performance:
-16.23%
1M Performance:
-44.26%
6M Performance:
-81.35%
1Y Performance:
-90.58%
1-Day Range:
$0.1701
$0.1888
1-Week Range:
$0.1701
$0.2342
52-Week Range:
$0.1701
$2.88
Senti Biosciences Holdings Inc Stock (SNTI) Company Profile
Name
Senti Biosciences Holdings Inc
Sector
Industry
Phone
(650) 239-2030
Address
2 CORPORATE DRIVE, FIRST FLOOR, SOUTH SAN FRANCISCO
Compare SNTI vs VRTX, REGN, MRNA, ARGX, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
SNTI
Senti Biosciences Holdings Inc
|
0.1884 | 5.87M | 38,000 | -51.55M | -37.07M | -1.9207 |
VRTX
Vertex Pharmaceuticals Inc
|
523.93 | 132.80B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
805.02 | 82.88B | 14.92B | 4.42B | 3.79B | 41.04 |
MRNA
Moderna Inc
|
200.10 | 79.89B | 2.23B | -3.19B | -1.60B | -8.1462 |
ARGX
Argen X Se Adr
|
873.71 | 54.94B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
377.63 | 42.72B | 5.76B | 514.49M | 1.10B | 4.4813 |
Senti Biosciences Holdings Inc Stock (SNTI) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | H.C. Wainwright | Buy |
| Jun-06-25 | Initiated | Laidlaw | Buy |
| Oct-07-22 | Initiated | Morgan Stanley | Equal-Weight |
Senti Biosciences Holdings Inc Stock (SNTI) Latest News
Senti Biosciences registers resale of 2.55 crore shares from notes - scanx.trade
Form 4 Senti Biosciences Holdings Inc For: 24 September By Investing.com - Investing.com India
Form 4 Senti Biosciences Holdings Inc For: 24 September By Investing.com - Investing.com UK
No cash at closing for Senti Biosciences (NASDAQ: SNTI) shareholders; future payments hinge on milestones. - Stock Titan
No cash at closing in Senti Biosciences (NASDAQ: SNTI)'s proposed merger; payments depend on milestones. - Stock Titan
Senti Biosciences (SNTI) refreshes auditor sign-off on shelf registration - Stock Titan
Senti Biosciences (NASDAQ: SNTI) Secures $2.5 Million Stock Purchase at Nasdaq Minimum Price Following Merger - Kalkine Media
Major backer lines up $2.5M for Senti Biosciences (NASDAQ: SNTI) if merger closes - Stock Titan
Convertible notes could hand one investor control of Senti (NASDAQ: SNTI) - Stock Titan
Senti Biosciences Holds Near $0.34 as SNTI Tests Key Support ZoneStrong Buy Stocks - dars.gov.et
Senti Biosciences Secures Equity Commitment Amid Merger Plans - TipRanks
Senti Biosciences Adds $2 Million Convertible Debt, $2.5 Million Equity Commitment Ahead of Merger - TradingView
Senti Biosciences Holdings, Inc.Common Stock (Nasdaq:SNTI) Stock Quote - The Chronicle-Journal
Senti Biosciences unit issues USD 2 million senior secured convertible notes to NSG BioInnovation Fund - Bitget
Senti Biosciences Inc (NASDAQ: SNTI) Share Price, SNTI Stock News, SNTI Share Price & Updates - Kalkine
Senti Biosciences amends securities agreement, adds note tranche - TipRanks
Senti Biosciences Holdings Received Notice of Noncompliance - TradingView
SNTI Q2'26 Earnings: EPS estimate is (0.27) USD - TradingView
Senti Biosciences Holdings, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2026 - marketscreener.com
Senti Biosciences (SNTI) Gains 2.35% as Shares Hold Above Key Support at $0.36Risk Reward Setups - vinanet.vn
Senti Biosciences (SNTI) Gains 2.35% as Shares Hold Above Key Support at $0.36Triple Bottom - dars.gov.et
Senti Biosciences (NASDAQ:SNTI) to spin off SENTI-202 pipeline to Celadon-backed NewCo via CVRs - Kalkine
SNTI|Senti Biosciences Inc|Price:0.373|Chg%:-0.030 - TradingKey
$Senti Biosciences (SNTI.US)$ - Moomoo
Senti Biosciences Holdings, Inc. SEC Filing (Jul 21, 2026) - Stock Titan
Senti Biosciences (SNTI) Hovers Near Support as Stock Consolidates Below $0.45ETF Outflow Streak - vinanet.vn
Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Nigeria
Form S-3/A Senti Biosciences Holdings Inc For: 16 July By Investing.com - Investing.com South Africa
Form 13D/A Senti Biosciences Holdings For: 16 July By Investing.com - Investing.com Canada
Senti Biosciences (SNTI) backer plans merger and $6M funding - Stock Titan
Form S-3/A Senti Biosciences Holdings Inc For: 16 July - Investing.com Canada
Senti Biosciences to spin off gene therapy unit for CVR - Investing.com
Senti Biosciences Holdings Announces Strategic Spin-Off of Gene-Circuit Pipeline and Plans Focus on Regulator Dial Platform - Quiver Quantitative
Senti Biosciences to Divest Operating Business to Celadon Affiliate; Holders Get Up to $60M CVRs - TradingView
Senti Biosciences Holdings, Inc. Announces a Strategic Transaction to Unlock Value for its Gene-Circuit-Enabled Pipeline, Including SENTI-202, and to Sharpen its Focus on Next-Generation Controllable Genetic Medicines Powered by its Regulator Dial™ Te - Yahoo Finance
Price to sales forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Price to book forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBITDA forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Enterprise value to EBIT forward of Senti Biosciences Holdings, Inc. – NASDAQ:SNTI - TradingView
Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI) - TradingView
Senti Biosciences Holdings Inc Actuals & Estimates (NASDAQ:SNTI) - TradingView
SNTI Forecast — Price Target — Prediction for 2027 - TradingView
SNTI Q1 2026 Earnings: Narrower Loss Surprises Amid Pre-Revenue StageGuidance Accuracy Score - dars.gov.et
Senti Biosciences (SNTI) registers 15.97M shares tied to May 2026 notes - Stock Titan
Senti Biosciences Inc (SNTI) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
SNTI Q1 2026 Earnings: Modest EPS Beat Amid Development ProgressEarnings Call Transcript - dars.gov.et
Senti Biosciences Inc (SNTI) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
The Radoff-JEC Group Highlights Seer Inc.’s and Chairman and CEO Omid Farokhzad, M.D.’s History of Value Destruction - Business Wire
SNTISenti Biosciences Holdings Inc Options - Finviz
Senti Biosciences Holdings Inc Stock (SNTI) Financials Data
Revenue
Net Income
Cash Flow
EPS
3.09%
0.72%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):